Company Overview and News

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

8h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-218604-02
CSSLF

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

8h sec.gov
Pricing Supplement No. F699 To Product Supplement No. I−A dated June 30, 2017, Prospectus Supplement dated June
CSSLF

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

8h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell these securities, and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated July 16, 2018.
CSSLF

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

11h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated July 16, 2018.
CSSLF

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

11h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated July 16, 2018.
CSSLF

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

14h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated July 16, 2018.
CSSLF

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

14h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated July 16, 2018
CSSLF

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

14h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated July 16, 2018.
CSSLF

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

19h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated July 13, 2018.
CSSLF

5
Boeing rethinks aerospace rulebook as ‘797’ plans take shape

2018-07-15 malaymail
CHICAGO, July 15 — Boeing Co is seeking to rewrite the rules for creating commercial jets as it hones plans for a new midrange jet nicknamed the 797.
DSLV VIIX DGLD CSSLF VIIZ SPR UTX CS CSGKF UGLD BOE ZIV USLV TVIX BA XIV

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

2018-07-13 sec.gov
Pricing Supplement No. U3093 To the Underlying Supplement dated April 19, 2018,
CSSLF

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

2018-07-13 sec.gov
Pricing Supplement No. F703 To Product Supplement No. I–A dated June 30, 2017,
CSSLF

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

2018-07-13 sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated July 13, 2018.
CSSLF

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

2018-07-13 sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-218604-02
CSSLF

1
CSSLF / Credit Suisse Group FORM 424B2 (Prospectus)

2018-07-13 sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completio
CSSLF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

46m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...